Literature DB >> 18180687

An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining.

Donald R Korb1, John P Herman, Victor M Finnemore, Joan M Exford, Caroline A Blackie.   

Abstract

PURPOSE: Sodium fluorescein is considered the premier dye for corneal staining and, similarly, rose bengal (RB) for conjunctival staining. A mixture of 1% fluorescein and 1% rose bengal has been reported as advantageous in daily practice. Mixtures of lissamine green with other ocular stains have not been reported. The purposes of this study were to review the clinical staining characteristics of fluorescein, rose bengal, and lissamine green in controlled dose and concentration and determine whether optimal staining of the cornea and bulbar conjunctiva are possible by using dye mixtures.
METHODS: Sixteen 10-microL solutions of fluorescein, rose bengal, lissamine green, and their mixtures were evaluated. Fourteen subjects with a diagnosis of dry eye were tested for staining with various combinations of the dyes. Examination of staining was made by using standard clinical practices.
RESULTS: A mixture of 2% fluorescein and 1% rose bengal was the most efficacious staining mixture for the cornea and conjunctiva, but moderate to marked discomfort was reported. The mixture of 2% fluorescein and 1% lissamine green did not result in discomfort and provided optimal corneal and conjunctival staining with only slightly less efficacy than 2% fluorescein and 1% rose bengal; 2% and 3% lissamine green produced burning and discomfort. The fluorescent characteristics of fluorescein were not significantly altered by the addition of 1% lissamine green. The preferred mixture for simultaneous and efficacious staining of the cornea and conjunctiva without an adverse sensation was 2% fluorescein and 1% lissamine green.
CONCLUSIONS: A mixture of 2% fluorescein and 1% lissamine green offers excellent simultaneous corneal and bulbar conjunctival staining and could replace the use of individual dyes for ocular staining and contact lens practice.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180687     DOI: 10.1097/ICL.0b013e31811ead93

Source DB:  PubMed          Journal:  Eye Contact Lens        ISSN: 1542-2321            Impact factor:   2.018


  12 in total

1.  Rose Bengal inhibits β-amyloid oligomers-induced tau hyperphosphorylation via acting on Akt and CDK5 kinases.

Authors:  Chen-Ye Mou; Yan-Fei Xie; Jia-Xin Wei; Qi-Yao Wang; Jing-Yang Le; Yong-Jie Bao; Pan-Pan Zhang; Yue-Chun Mao; Xing-Han Huang; Han-Bo Pan; C Benjamin Naman; Lin Liu; Hong-Ze Liang; Xiang Wu; Jia Xu; Wei Cui
Journal:  Psychopharmacology (Berl)       Date:  2022-10-12       Impact factor: 4.415

Review 2.  Efficacy of azithromycin 1% and 1.5% ophthalmic solutions compared to tobramycin 0.3% eye drops: A systematic review and meta-analysis.

Authors:  Birhanu Motbaynor Alemu; Teshager Worku
Journal:  SAGE Open Med       Date:  2020-09-18

3.  Impact of Improper Approach to Identify Lid Wiper Epitheliopathy (LWE).

Authors:  Christopher W Lievens; Yvonne Norgett; Nancy Briggs; Peter M Allen; Marta Vianya-Estopa
Journal:  Clin Ophthalmol       Date:  2020-10-06

4.  Lid Wiper Microvascular Responses as an Indicator of Contact Lens Discomfort.

Authors:  Zhihong Deng; Jianhua Wang; Hong Jiang; Zohra Fadli; Che Liu; Jia Tan; Jin Zhou
Journal:  Am J Ophthalmol       Date:  2016-08-16       Impact factor: 5.258

5.  Noninvasive Self-diagnostic Device for Tear Collection and Glucose Measurement.

Authors:  Seung Ho Lee; Yong Chan Cho; Young Bin Choy
Journal:  Sci Rep       Date:  2019-03-18       Impact factor: 4.379

6.  Reproducibility of Ocular Surface Staining in the Assessment of Sjögren Syndrome-Related Keratoconjunctivitis Sicca: Implications on Disease Classification.

Authors:  Astrid Rasmussen; Donald U Stone; C Erick Kaufman; Kimberly S Hefner; Nicole R Fram; Rhea L Siatkowski; Andrew J W Huang; James Chodosh; Pablo T Rasmussen; Dustin A Fife; Nathan Pezant; Kiely Grundahl; Lida Radfar; David M Lewis; Michael H Weisman; Swamy Venuturupalli; Daniel J Wallace; Nelson L Rhodus; Michael T Brennan; Courtney G Montgomery; Christopher J Lessard; R Hal Scofield; Kathy L Sivils
Journal:  ACR Open Rheumatol       Date:  2019-06-07

7.  A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.

Authors:  Mike Taylor; George Ousler; Gail Torkildsen; Claire Walshe; Matthew C T Fyfe; Adele Rowley; Steve Webber; John D Sheppard; Ajay Duggal
Journal:  Clin Ophthalmol       Date:  2019-02-12

8.  Analysis of the Association between Galectin-3 Concentration in Tears and the Severity of Dry Eye Disease: A Case-Control Study.

Authors:  Miki Hata-Mizuno; Yuichi Uchino; Miki Uchino; Shigeto Shimmura; Yoko Ogawa; Kazuo Tsubota; Kazuno Negishi
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

9.  Advances in Dry Eye Disease Examination Techniques.

Authors:  Yaying Wu; Chunyang Wang; Xin Wang; Yujie Mou; Kelan Yuan; Xiaodan Huang; Xiuming Jin
Journal:  Front Med (Lausanne)       Date:  2022-01-25

10.  Bioengineered Lacrimal Gland Organ Regeneration in Vivo.

Authors:  Masatoshi Hirayama; Kazuo Tsubota; Takashi Tsuji
Journal:  J Funct Biomater       Date:  2015-07-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.